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ABSTRACT
Bariatric surgery is known to attenuate glomerular hyperfiltration over the long term and thereby
protect the kidney from mechanical damage. Whether this effect is directly related to weight
loss or is independent of weight as are some of its other beneficial metabolic effects is not
known. We explored this question in a preliminary study that directly measured glomerular filtra-
tion rate (GFR) before, immediately after, and again many months after Roux-en-Y gastric bypass
after large weight loss had occurred. We simultaneously measured stimulated circulating gluca-
gon-like peptide-1, which is upregulated after Roux-en-Y gastric bypass and is a putative medi-
ator of GFR after bariatric surgery. We found no weight-independent effect of Roux-en-Y gastric
bypass on GFR nor an association between circulating GLP-1 levels and GFR. These findings, if
confirmed in larger studies, will help steer future enquiries in this area.
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Obesity is arguably the most important modifiable
cause of CKD in the modern era because it is prevalent
in nearly one in two patients with CKD and promotes
kidney damage through direct effects and intermediate
risk factors like diabetes and hypertension. Among its
most important direct adverse effects is glomerular
hyperfiltration, which can lead to maladaptive changes
that damage the glomerulus and proximal tubule [1].
Attenuation of obesity-related glomerular hyperfiltra-
tion is therefore an important strategy for
renoprotection.
Of all available weight reduction interventions bariat-
ric surgery offers the most effective and sustained
results. Bariatric surgery is also known to reverse glom-
erular hyperfiltration when measured months to years
post-operatively [2]. This has led to the belief that
attenuation of glomerular hyperfiltration is a direct result
of weight lost. However, this assumption may be incor-
rect. Studies in rodents and humans have reported
improvements in the glomerular filtration rate (GFR) and
albuminuria after bariatric surgery that are independent
of change in weight [2–4]. Bariatric surgery also has
weight-independent effects on other parameters like
glucose metabolism [5]. One putative mechanism for
this involves the rapid post-operative rise in circulating
glucagon-like peptide-1 (GLP-1), a hormone secreted by
intestinal cells that has several physiologic effects,
including enhancement of insulin secretion and
increased satiety [6]. GLP-1 has also been observed in
some but not all studies to mediate changes in GFR and
sodium handling [6–10]. The potent effects of GLP-1 are
manifested in the widely used drug class of GLP-
1 agonists.
In order to better understand the impact of weight
loss on GFR and circulating GLP-1 and their interrelation-
ship, we performed an exploratory study in which we
measured these parameters before, immediately after,
and many months after Roux-en-Y gastric bypass. Our
hypothesis was that there would be a weight independ-
ent effect on GFR that would be associated with
changes in circulating GLP-1.
Methods
Participants
Ten bariatric surgery patients were recruited from the
Indianapolis, IN, area with approval of the local
CONTACT Allon N. Friedman allfried@iu.edu Department of Medicine, Indiana University School of Medicine, 550 University Blvd, Suite 6100,
Indianapolis, IN, USA
 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
RENAL FAILURE
2020, VOL. 42, NO. 1, 624–628
https://doi.org/10.1080/0886022X.2020.1790389
investigational review board (#1105005352) and a data
safety & monitoring board. Exclusion criteria included
pregnancy, iodine allergy, cimetidine or trimethoprim
use, dialysis dependency and an expected life span of
<2 years. Pregnancy was excluded by urine test. Six
participants never completed the protocol due to tim-
ing of surgery, illness, or surgical complications. The
remaining four patients underwent Roux-en-Y gastric
bypass (RYGB). Two of the patients had insulin-depend-
ent diabetes and were instructed to hold their oral dia-
betes medications and insulin the day of the procedure.
Measurements
Patients fasted overnight before each visit. GFR was cal-
culated from iohexol (Omnipaque-300; GE Healthcare,
Piscataway, NJ) plasma clearance using a six-sample
method drawn over 6h. Blood samples were drawn from
a separate intravenous catheter. Plasma was isolated and
stored at 80C until measured. Plasma (100mL) under-
went protein precipitation with acetonitrile following
addition of internal standard para-aminobenzoic acid
(PABA). Supernatant was evaporated and reconstituted in
0.1% formic acid, 5% acetonitrile, 95% water and sepa-
rated using a Phenomenex C18 5uM 4.6 150nm col-
umn with gradient to 95% acetonitrile over 15min on an
Agilent 1100 HPLC (Santa Clara, CA) attached to a UV
detector (k¼ 254nm). Individual iohexol clearances (mL/
min) were calculated by standard noncompartmental
methods using Phoenix 64 v 8.0 (Certera, Princeton, NJ).
Iohexol clearance was calculated as dose divided by the
area under the plasma concentration-time curve (AUC)
from time zero to infinity.
Immediately prior to the injection of iohexol each
patient consumed an oral bolus of 120mL EnsureVR Plus
(6.6 g protein, 26 g carbohydrate, 5.6 g fat) as a mixed
meal tolerance test. Plasma samples were then drawn
at six time points over a 2-h period for measurement of
GLP-1. GLP-1active was measured using a commercial
ELISA kit (Millipore EZGLPHS-35K). The limit of detection
for GLP-1active was 0.14 pM. All samples were run in
duplicate on the same assay plate. We previously
reported that a mixed meal tolerance test provides a
strong stimulus for GLP-1 release [11].
Statistics
Peak GLP-1 levels after the mixed meal were identified
at 20min. Changes between peak and baseline (“Delta”)
were calculated. Given the preliminary nature of this
study and the small sample size, we used a one-sample
t-test to test if the average of differences between two
particular time points of interest for each individual
(e.g. participant #1, visit 1 vs. visit 2) is equal to zero
(SPSS, Armonk, NY). No adjustments were made for
multiple tests. Figures were made using SAS (Cary, NC).
Results
All participants were female and were 58, 59, 61, and
64 years old. GFR and weight remained statistically
unchanged in the first early visit after RYGB as com-
pared to pre-surgery but were both significantly lower
in the longer term (Table 1; Figures 1 and 2). In con-
trast, stimulated GLP-1 was higher at both post-surgery
time points compared to baseline (Table 1; Figure 3). Of
note, there was no correlation between change in
weight and change in GFR (p¼ 0.29) at the early post-
operative time point. There was also no clear pattern
between the presence of diabetes and changes in GFR
and GLP-1.
Discussion
Studies of bariatric surgery associated-weight loss on
kidney hemodynamics have traditionally compared pre-
surgery GFR levels to levels measured 1 year or later
post-surgery. This exploratory study is the first to have
directly measured GFR both very early and later after








(late post-surgery) V1 versus V2 V1 versus V3 V2 versus V3
Timing relative to bariatric surgery (days) 6 to 3 8 to 16 344 to 487 — — —
GFR (ml/min) 97 to 121 115 to 141 54 to 86 0.17 0.01 <0.01
Weight (kg) 112.2 to 134.2 112.3 to 127.4 74.8 to 89.9 0.16 0.01 <0.01
% Total weight loss (kg) — 0 to 6.7 20.9 to 40.1 — — <0.01
Fasting basal levels
GLP-1 (qmol/L)
2 to 49 5 to 18 2 to 29 0.83 0.81 0.91
Stimulated levels after mixed meal test
GLP-1 (qmol/L)
3 to 19 28 to 83 19 to 190 0.03 0.06 0.14
V1: Visit 1; V2: visit 2; V3: visit 3.
aRange.By one-sample t-test. P-value for testing whether the difference between different means is greater than zero.
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bariatric surgery to determine if changes in GFR are
independent of weight loss and correlated with changes
in GLP-1. The results offer insight into the gut-kidney
axis and the associated impact of bariatric surgery.
While we found, consistent with earlier reports, that
the long-term GFR is lower after RYGB compared to pre-
operative levels [2], we observed no reduction in GFR in
the early post-operative period. This is notable because
major metabolic improvements in the bariatric milieu are
known to occur at that time point even before appre-
ciable weight has been lost [12]. This weight-independent
effect is believed to be mediated by rapid changes in cir-
culating hormones and gut peptides such as GLP-1 and
possibly others [12]. The lack of a fall in GFR early on after
bariatric surgery suggests that the humoral changes
occurring at that time do not significantly influence GFR
or, alternatively, that countervailing effects are also upre-
gulated. Incidentally, and consistent with our previous
Figure 1. Early and later changes in weight after Roux-en-Y gastric bypass.
Figure 2. Early and later changes in measured GFR after Roux-en-Y gastric bypass.
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report [13], GFR was also not appreciably influenced by
the sharp reduction in dietary protein intake that typically
occurs immediately after bariatric surgery.
Obesity-associated glomerular hyperfiltration is
hypothesized to result from afferent arteriolar vasodila-
tion either directly or indirectly through deactivation
of tubuloglomerular feedback [14]. GLP-1 is part of the
gut-brain-kidney axis that helps mediate appetite,
weight, and metabolism and has also been reported to
have variable effects on regulating GFR and renal
tubular sodium reabsorption (which itself can influ-
ence tubuloglomerular feedback) [6–10]. While the
GFR remained unchanged early post-operatively com-
pared to baseline, stimulated GLP-1 secretion was as
expected significantly higher (Table 1; Figure 3). Of
note, fasting basal GLP-1 levels also did not track well
with changes in GFR (data not shown).
While our findings are certainly preliminary, it is
tempting to use them to reevaluate our understanding
of the determinants of obesity-related glomerular hyper-
filtration. A recent study by Chagnac and colleagues con-
cludes that the deactivated tubuloglomerular feedback
seen in obese individuals is a result of increased proximal
tubular sodium reabsorption, a finding that would be
expected to reverse early after weight loss [15] as sodium
avidity drops and natriuresis occurs [16]. The lack of a
reduction in GFR in our cohort early after bariatric surgery
raises the possibility that other mechanisms are
contributing to glomerular hyperfiltration. One potential
candidate is glomerular hypertrophy, which leads to a
higher GFR through increased glomerular capillary sur-
face area. It is possible that glomerular hypertrophy may
require longer periods than just a couple of weeks to
regress, thus explaining why we did not observe a lower
GFR early after bariatric surgery.
Our study was limited by small size and the inclusion
of a mixed population (persons with and without dia-
betes). Despite these drawbacks, we were still able to
identify statistically significant differences at several
times points between variables without any clear dis-
tinction noted between persons with or without dia-
betes. Additionally, GFR measurements were not
performed in the fasting state at each visit as is trad-
itionally done in order to stimulate a GLP-1 response as
protocol usually requires. However, the amount of pro-
tein we provided (0.05g/kg) to stimulate GLP-1 release
was far smaller than the protein stimulus usually used
to measure renal reserve (1 g/kg). Due to restrictions
on available resources, we were also unable to analyze a
complete array of candidate hormones and collect urine
to assess sodium handling. Such testing should be cer-
tainly performed in future studies with larger
populations.
In summary, we found no weight-independent effect
of Roux-en-Y gastric bypass on GFR nor any association
between GFR and circulating GLP-1. These findings, if
Figure 3. Early and later changes in Delta20min-baseline in GLP-1 after Roux-en-Y gastric bypass. Peak GLP-1 is defined as the differ-
ence in levels from baseline to 20min after a mixed meal.
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confirmed in larger studies, will help steer future enqui-
ries in this area.
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